Engineered protein therapeutics offer advantages, including strong target affinity, selectivity, and low toxicity, but like natural proteins can be susceptible to proteolytic degradation, thereby limiting their effectiveness. A compelling therapeutic target is mesotrypsin, a protease upregulated with tumor progression, associated with poor prognosis, and implicated in tumor growth and progression of many cancers.
However, with its unique capability for cleavage and inactivation of proteinaceous inhibitors, mesotrypsin presents a formidable challenge to the development of biologic inhibitors. We used a powerful yeast display platform for directed evolution, employing a novel multi-modal library screening strategy, to engineer the human amyloid precursor protein inhibitor (APPI) simultaneously for increased proteolytic stability, stronger binding affinity, and improved selectivity for mesotrypsin inhibition. We identified a triple mutant APPI M17G/I18F/F34V , with 1459-fold improved affinity, up to 350,000-fold greater specificity, and 83-fold improved proteolytic stability vs wild-type APPI. We demonstrated that APPI M17G/I18F/F34V acts as a functional inhibitor in cell-based models of mesotrypsin-dependent prostate cancer cellular invasiveness. Additionally, by solving the crystal structure of the APPI M17G/I18F/F34V /mesotrypsin complex, we obtained new insights into the structural and mechanistic basis for improved binding and proteolytic resistance. Our study identifies a promising mesotrypsin inhibitor as a starting point for development of anticancer protein therapeutics.
